Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway

被引:158
作者
Hao, L [1 ]
Du, M [1 ]
Lopez-Campistrous, A [1 ]
Fernandez-Patron, C [1 ]
机构
[1] Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada
基金
加拿大健康研究院;
关键词
matrix metalloproteinase; heparin-binding epidermal growth factor; epidermal growth factor receptor; vasoconstriction; hypertension;
D O I
10.1161/01.RES.0000109413.57726.91
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Matrix metalloproteinase (MMP)-dependent shedding of heparin-binding epidermal growth factor (HB-EGF) and subsequent activation of the EGF receptor (EGFR) in the cardiovasculature is emerging as a unique mechanism signaling growth effects of diverse G protein-coupled receptors (GPCRs). Among these GPCRs are adrenoceptors and angiotensin receptors that contribute to the pathogenesis of hypertension through their vasoconstrictive and growth effects. Focusing on alpha(1b)-adrenoceptors, we suggest here that MMP-dependent activation of the EGFR promotes vasoconstriction as well as growth. We identified MMP-7 as a major HB-EGF sheddase in rat mesenteric arteries and alpha(1b)-adrenoceptors, angiotensin receptors, and hypertension-stimulated MMP-7 activity. Adrenoceptors stimulated EGFR autophosphorylation in arteries, and this transactivation was opposed by the MMP-7 inhibitor GM6001 as well as MMP-7-specific antibodies. In isolated microperfused arteries, blockade of EGFR transactivation with inhibitors of the EGFR (AG1478 and PD153035), HB-EGF (CRM197 and neutralizing antibodies), or MMPs (doxycycline) inhibited adrenergic vasoconstriction. In spontaneously hypertensive rats but not in normotensive rats, the inhibition of MMPs with doxycycline (19.2 mg/d from week 7 until week 12) reduced systolic blood pressure and attenuated HB-EGF shedding in the mesenteric arteries. These findings suggest a previously unknown mechanism of vasoregulation whereby agonists of certain GPCRs (such as adrenoceptors and angiotensin receptors) activate MMPs (such as MMP-7) that shed EGFR ligands (such as HB-EGF), which then activate the EGFR, thereby promoting vasoconstriction as well as growth. Because this mechanism is triggered by agonists typically overexpressed in hypertension, its blockade may have therapeutic potential for simultaneously inhibiting pathological vasoconstriction and growth in hypertensive disorders.
引用
收藏
页码:68 / 76
页数:9
相关论文
共 29 条
[1]   Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy [J].
Asakura, M ;
Kitakaze, M ;
Takashima, S ;
Liao, Y ;
Ishikura, F ;
Yoshinaka, T ;
Ohmoto, H ;
Node, K ;
Yoshino, K ;
Ishiguro, H ;
Asanuma, H ;
Sanada, S ;
Matsumura, Y ;
Takeda, H ;
Beppu, S ;
Tada, M ;
Hori, M ;
Higashiyama, S .
NATURE MEDICINE, 2002, 8 (01) :35-40
[2]   Prospective, randomized, double-blind trial investigating the effect of doxycycline on matrix metalloproteinase expression within atherosclerotic carotid plaques [J].
Axisa, B ;
Loftus, IM ;
Naylor, AR ;
Goodall, S ;
Jones, L ;
Bell, PRF ;
Thompson, MM .
STROKE, 2002, 33 (12) :2858-2864
[3]  
CARPENTER G, 2000, SCI STKE, V15, P1
[4]   Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease [J].
Cowan, KN ;
Jones, PL ;
Rabinovitch, M .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (01) :21-34
[5]   Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction [J].
Fernandez-Patron, C ;
Stewart, KG ;
Zhang, YL ;
Koivunen, E ;
Radomski, MW ;
Davidge, ST .
CIRCULATION RESEARCH, 2000, 87 (08) :670-676
[6]  
Fernandez-Patron C, 1999, CIRC RES, V85, P906
[7]  
Fernandez-Patron C, 1999, THROMB HAEMOSTASIS, V82, P1353
[8]   Epidermal growth factor receptor transactivation mediates the tonic and fibrogenic effects of endothelin in the aortic wall of transgenic mice [J].
Flamant, M ;
Tharaux, PL ;
Placier, S ;
Henrion, D ;
Coffman, T ;
Chatziantoniou, C ;
Dussaule, JC .
FASEB JOURNAL, 2002, 16 (14) :327-+
[9]   Epidermal growth factor: a potent vasoconstrictor in experimental hypertension [J].
Florian, JA ;
Watts, SW .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1999, 276 (03) :H976-H983
[10]   Enhanced expression of heparin-binding EGF-like growth factor and its receptor in hypertrophied left ventricle of spontaneously hypertensive rats [J].
Fujino, T ;
Hasebe, N ;
Fujita, M ;
Takeuchi, K ;
Kawabe, J ;
Tobise, K ;
Higashiyama, S ;
Taniguchi, N ;
Kikuchi, K .
CARDIOVASCULAR RESEARCH, 1998, 38 (02) :365-374